Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2Medical Oncology 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × roniciclib × Clear all
NCT01188252 2017-01-09

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

Bayer

Phase 1 Completed
112 enrolled
Tumor-Agnostic

Neoplasms

NCT02390154 2016-07-15

Roniciclib Mass Balance Study

Bayer

Phase 1 Completed
7 enrolled
Tumor-Agnostic

Neoplasms

NCT02457351 2016-05-23

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Bayer

Phase 1 Completed
14 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡